Compare Cronos Group Inc (CRON) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs GSK plc — how do they compare? Cronos Group Inc trades at $3.15 (market cap $1.14B), while GSK plc trades at $50.29 (market cap $102.60B). The key difference: GSK plc is far larger — about 90× Cronos Group Inc's market cap, and GSK plc pays a 3.57% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | GSK | |
|---|---|---|
Market Cap | $1.14B | $102.60B |
Sector | Health | Health |
52-Week High | $3.27 | $61.18 |
52-Week Low | $2.30 | $38.22 |
Enterprise Value | $341.13M | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cronos Group (CRON) trades at $3.125, up 4.17% today. The stock shows a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with $0.09 EPS versus $0.01 expected, driven by 58% YoY revenue growth. However, the company posted a net loss of $9.45M in 2025, though margins are improving from prior years.
Outlook is mixed; strong international expansion and product launches support growth, but negative cash flow and intense competition pose risks. Analyst consensus is cautious with 60% hold ratings. The stock offers growth potential but requires monitoring of profitability and cash management.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
